Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. grew its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 5.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,411 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,566 shares during the quarter. Principal Financial Group Inc. owned approximately 0.52% of Supernus Pharmaceuticals worth $8,899,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of SUPN. Bank of New York Mellon Corp boosted its holdings in Supernus Pharmaceuticals by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 425,387 shares of the specialty pharmaceutical company’s stock worth $11,379,000 after buying an additional 2,427 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Supernus Pharmaceuticals by 20.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,083 shares of the specialty pharmaceutical company’s stock worth $350,000 after acquiring an additional 2,225 shares during the last quarter. Commonwealth Equity Services LLC increased its position in shares of Supernus Pharmaceuticals by 3.6% during the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock worth $273,000 after purchasing an additional 350 shares in the last quarter. nVerses Capital LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at $72,000. Finally, Rhumbline Advisers lifted its holdings in Supernus Pharmaceuticals by 3.3% in the 2nd quarter. Rhumbline Advisers now owns 180,274 shares of the specialty pharmaceutical company’s stock valued at $4,822,000 after purchasing an additional 5,813 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $36.91 on Tuesday. The stock’s fifty day moving average is $35.88 and its two-hundred day moving average is $32.61. The firm has a market capitalization of $2.04 billion, a P/E ratio of 34.50 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $39.37.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to analysts’ expectations of $157.35 million. During the same quarter in the previous year, the company posted ($0.29) EPS. The company’s revenue was up 14.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on SUPN shares. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insider Activity at Supernus Pharmaceuticals

In other news, Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $36.62, for a total value of $520,480.06. Following the sale, the director now directly owns 13,315 shares of the company’s stock, valued at approximately $487,595.30. The trade was a 51.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of the stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total transaction of $4,585,000.00. Following the transaction, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. The trade was a 11.89 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 154,213 shares of company stock worth $5,660,180. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.